Patrick Hsu: A New DNA Editing Technology Reported In Science Magazine
Patrick Hsu, Co-Founder of Arc Institute, posted on LinkedIn:
”Today in Science Magazine, we report a new DNA editing technology to seamlessly write massive changes into the right place in the human genome.
The reason gene editing hasn’t transformed human health is that current gene editing technologies like CRISPR are very limited.
The problem with CRISPR is that it cuts up your DNA, and then hopes that unreliable cellular DNA repair will make the wanted edit.
famously called it genome vandalism. More precise versions of CRISPR only edit less than 100 bases – often only a single base. Therefore, it’s not suited to make large changes safely.
However, most diseases are not the result of mutations in one location. Instead, their causes are spread all across the 3 billion base pairs in the genome.
We found bridge RNAs in bacterial “jumping genes” that allow us to make safe and arbitrary changes (insert, cut out, or flip) to every nucleotide within (up to) a 1 million bp sequence in your DNA.
In the paper, we show that we can correct the disease-causing DNA repeats that cause Friedreich’s ataxia (which is a rare neurological disease). The same approach could be applied to Huntington’s and other repeat expansion disorders.
This work was a wonderful collaboration with my Arc Institute cofounder Silvana Konermann and led by the indefatigable Nicholas Perry, alongside our amazing bridge editing team: Liam Bartie, Dhruva Katrekar, Gabriel Gonzalez, Matthew Durrant, James Pai, Alison Fanton, Juliana Martins, Masahiro Hiraizumi, Chiara Ricci-Tam, and Hiroshi Nishimasu”
Read the full article here.
Title: Megabase-scale human genome rearrangement with programmable bridge recombinases
Authors: Nicholas T. Perry, Liam J. Bartie, Dhruva Katrekar, Gabriel A. Gonzalez, Matthew G. Durrant, James J. Pai, Alison Fanton, Juliana Q. Martins, Masahiro Hiraizumi, Chiara Ricci-Tam, Hiroshi Nishimasu, Silvana Konermann, Patrick D. Hsu
Stay updated with Hemostasis Today.
-
Nov 10, 2025, 10:16Pablo Corral on Enlicitide: The Phase 3 CORALreef HeFH Trial Brings a Major Step Forward
-
Nov 10, 2025, 10:15Laurent Bertoletti Invites You to the Joint INNOVTE and GITA Meeting on Hormones and Thrombosis
-
Nov 10, 2025, 10:15Christopher Cannon: DOAC Monotherapy Wins Again
-
Nov 10, 2025, 10:14Marieke Kruip on Sex differences in Outcomes of VKA Treatment in Patients with Mechanical Heart Valve
-
Nov 10, 2025, 10:14Ana Paula Lacombe: From Research to Bedside, Innovation in Stroke Care is Moving Fast!
-
Nov 10, 2025, 10:13Jan Sloves: Understanding Iliofemoral DVT – What You Can’t Afford to Miss
-
Nov 10, 2025, 10:12Mohamed Rawy Shares a Comprehensive Guide For Anticoagulation
-
Nov 10, 2025, 10:10Marc Carrier: Proud to Share the Results of the WAVe Study
-
Nov 10, 2025, 10:07Frederik Denorme – The New PI at the Laboratory of Cell Biology and Histology at University of Antwerp